All articles by GlobalData Healthcare

GlobalData Healthcare
Pfizer’s etrasimod aims to differentiate UC market with strong safety profile
The UC market is forecasted to reach 2031 sales of approximately $9.6bn across the 8MM.
AbbVie and Genmab’s bispecific Epkinly has a first-to-market advantage in DLBCL
GlobalData’s consensus forecast forecasts that Epkinly will achieve blockbuster status by 2027.
Johnson & Johnson’s Tremfya outshines IL-17 inhibitors as plaque psoriasis treatment
The trial exhibited superior and durable clinical efficacy and safety of Tremfya.
Role of machine learning tools in early diagnosis of Parkinson’s disease
GlobalData epidemiologists forecast that there are currently over 2.4 million diagnosed prevalent cases of PD in 7MM.
The troubling health impacts of air pollution
Key pollutants of interest included black carbon, small particulate matter (PM₂.₅), nitrogen dioxide (NO₂), and sulphur dioxide (SO₂).
Top three unmet needs to target in Parkinson’s disease
In the early stages of Parkinson’s disease, motor symptoms are well managed by levodopa.
Childhood adversity potentially pre-disposes young adults to type 2 diabetes
GlobalData estimate that by the end of 2023, there will be 234 million diagnosed prevalent cases of type 2 diabetes in men and women in the 16 major pharmaceutical markets.
Rate of breast density loss may indicate risk of breast cancer
In 2023, GlobalData epidemiologists predict over 278,000 diagnosed incident cases of invasive breast cancer.
National Lipid Day: a timely reminder of dyslipidemia
Several risk factors can contribute to the development of dyslipidemia, including consuming a diet high in saturated fats.